Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03416179 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 730
- Enrollment target
NCT03416179 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 730 participants.
The verdict
NCT03416179, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 730 participants
- Enrollment target
Study Summary
Glasdegib is being studied in combination with azacitidine for the treatment of adult patients with previously untreated acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy (Non-intensive AML population). Glasdegib is being studied in combination with cytarabine and daunorubicin for the treatment of adult patients with previously untreated acute myeloid leukemia (Intensive AML population).
Interventions
- DRUG Placebo
- DRUG azacitidine
- DRUG glasdegib
- DRUG daunorubicin + cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 730 participants |
| Start Date | 2018-04-20 |
| Est. Completion | 2022-01-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03416179
The ClinicalTrials.gov registry entry for NCT03416179 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 730 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03416179 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03416179 about?
NCT03416179 is a clinical study titled "A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia". Glasdegib is being studied in combination with azacitidine for the treatment of adult patients with previously untreated acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy (Non-intensive AML population). Glasdegib is being studied in combination with cytarabine...
What is the current status of trial NCT03416179?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 730 participants. The study started on 2018-04-20. Estimated completion is 2022-01-17.
What interventions are being tested in trial NCT03416179?
The interventions under investigation include: Placebo (DRUG), azacitidine (DRUG), glasdegib (DRUG), daunorubicin + cytarabine (DRUG).
Who is sponsoring clinical trial NCT03416179?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.